gainbot
BriefMoversScreensSectorsEarningsIPOsNewsDividends & splitsScreenerWatchlistLearn
NASDAQ · BMRNHealthcarePharmaceuticals

BioMarin Pharmaceuticals Inc (BMRN)

$57.13+2.64%
Close Nov 4, 2026 · split-adjusted
Nov 4, 2026$56.65▲ 7.19% in range
Nov 3, 2025Low $49.67 · High $70.24Nov 4, 2026
What changed · written from our data
As of Nov 4, 2026

BioMarin Pharmaceuticals closed at $57.13 on Nov 4, up 2.64%, 18.7% below its 52-week closing high. Volume of 3.2M shares was 1.23× its 20-day average (close to normal).

Split-adjusted performance: +1.6% over one month, +4.6% over six months, +8.1% over one year.

In the quarter ended Jun 30, 2026, revenue was $989.71M, up 19.9% from a year earlier, with a net margin of 4.5%.

Short interest was 12.1M shares at the Oct 15 settlement, up 4.6% from the prior report (6.2% of float, 4.9 days to cover).

Market cap$11.06B193.6M shares
Revenue · quarter$989.7M+19.9% YoY
Diluted EPS$0.23−81.3% YoY
P/E · TTM151.5×P/S 3.2×
Net margin4.5%Gross 79.5%
Dividend yieldNone
52-week range49.67 – 70.24−18.7% from high
Volume3.2M1.23× 20-day avg
Volatility · 60d27.2%Annualised
Short % of float6.2%4.9 days to cover
Net cash-$3.31BCash $874.0M
Next earnings—Not scheduled
Split-adjusted performance
1W +2.0%1M +1.6%3M −7.0%6M +4.6%YTD −3.9%1Y +8.1%3Y −29.5%5Y −20.3%

Earnings reactions

History →

No reported quarters with price history yet.

Rank within Pharmaceuticals

Percentile among 420 companies (100 = best)

6-month momentum74
Revenue growth67
Net margin75
Value (low P/E)2
Size95

Industry medians: 6-month return −25.5%, revenue growth +6.2%, net margin −33.8%, P/E 16.1×.

Short interest

Details →
Shares short12.1M+4.6% vs prior
Days to cover4.9Settled Oct 15
% of float6.2%
Short vol. 10d65.7%of daily volume

Closest peers by size in Pharmaceuticals

CompanyPriceToday6MRev. growthNet marginP/EMkt cap
BMRNBioMarin Pharmaceuticals$57.13+2.64%+4.6%+19.9%4.5%151.5$11.06B
ELANElanco Animal Health Incorporated$25.31+3.01%−3.3%+10.2%3.9%—$12.65BCompare
SMMTSummit Therapeutics$16.17+2.34%−9.4%———$12.90BCompare
TGTXTG Therapeutics$61.63+1.45%+46.8%+70.3%3.2%21.4$9.43BCompare
PTGXProtagonist Therapeutics$143.37+2.23%+37.9%+3749.2%76.3%111.9$9.28BCompare
SYRESpyre Therapeutics$99.04−0.23%+35.7%———$9.26BCompare
MDGLMadrigal Pharmaceuticals$400.43+1.04%−25.8%+50.1%12.9%—$9.25BCompare
CYTKCytokinetics$63.60+2.07%−15.0%−57.1%−694.4%—$8.84BCompare
ARWRArrowhead Research$61.65+3.56%−22.1%+171.0%−258.2%—$8.71BCompare

News about BioMarin Pharmaceuticals

All news →
BioMarin (BMRN) Q3 Earnings: Taking a Look at Key Metrics Versus EstimatesZacks Investment Research · 2d ago▲ PositiveBioMarin Pharmaceutical (BMRN) Q3 Earnings Surpass EstimatesZacks Investment Research · 2d agoNeutralBioMarin Pharmaceutical (BMRN) Earnings Expected to Grow: Should You Buy?Zacks Investment Research · Oct 19, 2026▲ PositiveBioMarin Stops Voxzogo Development for Noonan SyndromeZacks Investment Research · Sep 16, 2026NeutralHow BioMarin Turned a Competitive Threat Into a Royalty-Bearing AssetZacks Investment Research · Sep 3, 2026▲ Positive

Quick answers

What does BioMarin Pharmaceuticals do?
BioMarin is a global biotechnology company focused on developing and commercializing therapies for rare genetic diseases. BioMarin specializes in enzyme replacement therapies, gene therapies, and other advanced treatments designed to address complex genetic disorders.
What is BMRN's market cap?
$11.06B, based on the Nov 4 close of $57.13.
What is BMRN's P/E ratio?
151.5× trailing-twelve-month earnings of $72.97M.
Does BioMarin Pharmaceuticals pay a dividend?
No regular cash dividend has been paid in the last year.
How much of BMRN is sold short?
12.1M shares, 6.2% of float, as of Oct 15, 2026.
What sector is BMRN in?
Healthcare, in the Pharmaceuticals industry.

About BioMarin Pharmaceuticals

BioMarin is a global biotechnology company focused on developing and commercializing therapies for rare genetic diseases. BioMarin specializes in enzyme replacement therapies, gene therapies, and other advanced treatments designed to address complex genetic disorders. The company has eight approved therapies for conditions including achondroplasia, phenylketonuria, hemophilia, and mucopolysaccharidosis. BioMarin has an expanding, yet relatively early-stage, pipeline of treatments in development across skeletal conditions and enzyme therapies.

HQ: Novato, CA3,221 employeesListed Jul 23, 1999biomarin.com

Sources: Massive / Polygon daily aggregates (split-adjusted) · SEC filings via Massive · FINRA settlements via Massive · Financial Modeling Prep. Figures are dated where shown; research is informational, not investment advice. Methodology